Cantor Fitzgerald restated their buy rating on shares of Heron Therapeutics, Inc. (NASDAQ:HRTX) in a report published on Thursday morning. The firm currently has a $31.00 target price on the biotechnology company’s stock.
Several other research analysts have also recently issued reports on the stock. Oppenheimer Holdings, Inc. assumed coverage on shares of Heron Therapeutics in a report on Monday, October 30th. They set a buy rating and a $27.00 target price on the stock. Noble Financial reiterated a buy rating and set a $24.00 target price on shares of Heron Therapeutics in a report on Friday, October 6th. Northland Securities assumed coverage on shares of Heron Therapeutics in a report on Wednesday, September 27th. They set an outperform rating and a $40.00 target price on the stock. Mizuho assumed coverage on shares of Heron Therapeutics in a report on Tuesday, September 26th. They set a buy rating and a $28.00 target price on the stock. Finally, BidaskClub upgraded shares of Heron Therapeutics from a sell rating to a hold rating in a report on Saturday, August 26th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have given a buy rating to the stock. Heron Therapeutics presently has an average rating of Buy and a consensus price target of $28.36.
Heron Therapeutics (NASDAQ HRTX) traded up $0.55 during midday trading on Thursday, hitting $16.05. 806,710 shares of the stock were exchanged, compared to its average volume of 636,486. The company has a current ratio of 2.82, a quick ratio of 2.72 and a debt-to-equity ratio of 0.36. Heron Therapeutics has a 12-month low of $12.21 and a 12-month high of $20.85.
Heron Therapeutics (NASDAQ:HRTX) last posted its quarterly earnings results on Wednesday, August 9th. The biotechnology company reported ($0.80) EPS for the quarter, topping the Zacks’ consensus estimate of ($0.90) by $0.10. The company had revenue of $8.51 million during the quarter, compared to the consensus estimate of $4.53 million. equities research analysts anticipate that Heron Therapeutics will post -3.49 earnings per share for the current year.
Several hedge funds have recently added to or reduced their stakes in HRTX. Janus Henderson Group PLC purchased a new stake in shares of Heron Therapeutics during the second quarter valued at about $78,134,000. Vanguard Group Inc. lifted its position in shares of Heron Therapeutics by 40.2% during the first quarter. Vanguard Group Inc. now owns 1,875,103 shares of the biotechnology company’s stock valued at $28,127,000 after buying an additional 537,563 shares during the last quarter. State Street Corp lifted its position in shares of Heron Therapeutics by 30.7% during the first quarter. State Street Corp now owns 1,787,678 shares of the biotechnology company’s stock valued at $26,822,000 after buying an additional 420,113 shares during the last quarter. Point72 Asset Management L.P. purchased a new stake in shares of Heron Therapeutics during the first quarter valued at about $2,002,000. Finally, Credit Suisse AG lifted its position in shares of Heron Therapeutics by 329.8% during the first quarter. Credit Suisse AG now owns 144,061 shares of the biotechnology company’s stock valued at $2,161,000 after buying an additional 110,539 shares during the last quarter.
Heron Therapeutics Company Profile
Heron Therapeutics, Inc is a biotechnology company engaged in developing pharmaceutical products for patients suffering from cancer or pain. The Company’s product candidates include SUSTOL, HTX-019 and HTX-011. All of its product candidates utilize science and technology platforms, including its Biochronomer drug delivery technology.
What are top analysts saying about Heron Therapeutics Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Heron Therapeutics Inc. and related companies.